/ /

  • linkedin
  • Increase Font
  • Sharebar

    Keeping up with the latest diabetic eye disease research

    ARVO’s Diabetic Retinopathy meeting brought a wealth of new information



    1. Mishra M, Kowluru RA. Epigenetic Modification of Mitochondrial DNA in the Development of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5133-42.

    2. Kramerov AA, Ljubimov AV. Stem cell therapies in the treatment of diabetic retinopathy and keratopathy. Exp Biol Med (Maywood). 2015 Oct 9.

    3. Saghizadeh M, Dib CM, Brunken WJ, et al. Normalization of wound healing and stem cell marker patterns in organ-cultured human diabetic corneas by gene therapy of limbal cells. Exp Eye Res. 2014 Dec;129:66-73.

    4. Hubbi ME, Semenza GL.Regulation of cell proliferation by hypoxia-inducible factors. Am J Physiol Cell Physiol. 2015 Dec 15;309(12):C775-82.

    5. Sun JK, Radwan SH, Soliman AZ, et al. Neural Retinal Disorganization as a Robust Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema. Diabetes. 2015 Jul;64(7):2560-70.

    6. Burns SA, Elsner AE, Chui TY, et al. In vivo adaptive optics microvascular imaging in diabetic patients without clinically severe diabetic retinopathy. Biomed Opt Express. 2014 Feb 27;5(3):961-74.

    7. Giacco F, Du X, Carratú A, et al. GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop. Diabetes. 2015 Sep;64(9):3273-84.

    8. Chous AP, Richer SP, Gerson JD, et al. The Diabetes Visual Function Supplement Study (DiVFuSS). Br J Ophthalmol. 2016 Feb;100(2):227-34

    9. Kowluru RA, Zhong Q, Santos JM, et al. Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutr Metab (Lond). 2014 Jan 30;11(1):8


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Optometry Times A/V